ÂÜÀòÂÒÂ×

Greg Coffey has a diverse background in the pharmaceutical industry, with experience in leadership roles and scientific research. Greg is currently serving as the Vice President of Immunology and Clinical Translational Research at Nuvig Therapeutics Inc., where they lead the strategic planning and execution of the company's R&D programs. Greg'sresponsibilities include overseeing pre-clinical studies, authoring IND modules, and developing clinical pharmacodynamic assays.

Prior to their current role, Greg worked as the Senior Director of Clinical Translational Medicine at Alexion Pharmaceuticals, Inc., where they were responsible for overseeing translational sciences for immunology-related programs. Greg worked closely with project teams to assess translational science needs, develop assays, and analyze data to identify biomarkers of clinical response.

Before joining Alexion Pharmaceuticals, Greg held various roles at Portola Pharmaceuticals. As the Senior Director of Biology and In Vivo Pharmacology, they led the cerdulatinib clinical development program, communicated with the executive team and board of directors, and managed research groups. Greg also served as a Scientist II to Director of Biology, leading efforts in identifying lead candidates and taking two programs from early research to the clinic.

Greg's career began at Stanford University School of Medicine, where they worked as a Post-Doctoral Fellow in the Laboratory of Ronald and Shoshana Levy. Greg'sresearch focused on cell signaling pathways related to B cell oncogenesis and hepatitis C virus infection.

Greg started their career at Genentech as an Associate Scientist, where they conducted studies on the stability and tissue pharmacokinetics of therapeutic monoclonal antibodies.

Overall, Greg Coffey has a strong track record in leadership, research, and development within the pharmaceutical industry.

Greg Coffey's education history includes obtaining a Doctor of Philosophy (Ph.D.) degree in Molecular Biology with a focus on DNA repair. Greg attended the University of Minnesota School of Medicine from 1997 to 2002.